Ovarian Neoplasms, Platinum-resistant, BRCA wild type, PARP inhibitor, Immunotherapy
Ovarian cancer, PARP inhibitor, Prognosis, recurrence, Survival
Uterine Cervical Neoplasms, Oligometastasis, Stereotactic Ablative Body Radiotherapy, Programmed Cell Death Ligand 1